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Abstract
Background: The impact of autoimmune diseases on pregnancy remains understudied on a 
population level. Examination of obstetric and neonatal outcomes among women with 
autoimmune disease and their infants can provide important insights for clinical management.
Methods: Autoimmune diseases and outcomes were identified using medical records. Cesarean 
delivery, preterm birth, preeclampsia, small for gestational age (SGA), neonatal intensive care 
(NICU) admission, neonatal respiratory distress syndrome (RDS), and perinatal mortality risk was 
assessed. Poisson regression with robust standard errors estimated relative risks (RR) and 95% 
confidence intervals (95% CI) with adjustment for maternal characteristics and other chronic 
conditions.
Results: Women with T1DM were at increased risk for nearly all outcomes including RDS (RR: 
3.62; 95% CI: 2.84, 4.62), perinatal mortality (RR: 2.35; 95% CI: 1.12, 4.91), cesarean delivery 
(RR: 2.16; 95% CI: 2.02, 2.32) and preterm birth (RR: 3.52; 95% CI: 3.17, 3.91). Women with 
SLE also had higher risk for preterm delivery (RR: 2.90; 95% CI: 2.42, 3.48) and RDS (RR:2.99; 
95% CI: 1.99, 4.51) as did women with Crohn’s (cesarean delivery RR:1.31, 95% CI: 1.08, 1.60; 
preterm delivery RR: 1.84, 95% CI: 1.37, 2.49. RA increased risk for SGA (RR:1.66; 95% CI: 
1.08, 2.55).
Conclusion(s): Despite the heterogeneity in autoimmune diseases, we observed elevated 
preterm birth risk for most women with autoimmune disease. SLE and T1DM appeared to confer 
increased risk for a wide range of adverse outcomes.
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1. Introduction
The worldwide estimated cumulative prevalence of autoimmune disease is approximately 
5% [1], and increasing [2]. Approximately 66% of autoimmune diseases have a mean age of 
onset less than 50 years [1], and 80% of autoimmune cases in the U.S. occur among women 
[3,4]. It is important to understand the effect autoimmune diseases have on pregnant women 
and their infants.
The physiologic regulation of inflammation during pregnancy plays an important function in 
obstetric and neonatal outcomes. Inflammation, an immune-mediated response, assists in 
implantation and placentation early in pregnancy. Inflammation also promotes parturition 
and placental expulsion [5]. Later in gestation, pro-inflammatory processes at the maternal/
fetal interface due to infection or placental abruption may lead to preterm birth, 
preeclampsia, and other adverse outcomes [6]. Research into the etiology of these outcomes 
is warranted. Inflammation is a key feature of autoimmune disease [3,4,7]. However, the 
population-level impact of autoimmune diseases on pregnancy remains understudied. Our 
previous work found women with asthma or thyroid disease had an increased risk for poor 
obstetric and infant outcomes [8–10], yet not all cases of asthma or thyroid disease are 
autoimmune. The underlying biologic mechanisms linking autoimmune disease and 
increased risk of adverse obstetric and neonatal outcomes are not well understood yet may 
result from overlapping physiologic adaptations necessary for pregnancy [11,12], their 
disease states [13–20], the presence of autoantibodies or medications [21,22] required for 
management during pregnancy [17,21,23,24].
A challenge in studying the association of autoimmune diseases with obstetric and neonatal 
outcomes is the rarity of both. Research conducted to date is largely among homogenous 
populations outside the U.S. [14–17,22,25–41]. Studies conducted among U.S. populations 
are often limited by small sample sizes [21,30,40] or focused on a specific autoimmune 
disease and lacked detailed data on multiple obstetric and infant outcomes [34,42,43].
Cesarean delivery and preterm delivery are most frequently examined in the existing 
literature. Women with type 1 diabetes mellitus (T1DM) [12,32,41,44], systemic lupus 
erythematosus (SLE) [45–48], Crohn’s disease [49–52] or rheumatoid arthritis (RA) 
[22,53,54] are reported to be at increased risk for cesarean delivery but evidence among 
women with multiple sclerosis (MS) is mixed. Two population-based studies found women 
with MS had approximately 40% higher risk for cesarean delivery [27,28], while two other 
population-based studies [26,55] and two small case-control studies [25,56] found no 
increased risk. In addition, prior studies did not explore the indications or timing of cesarean 
deliveries (prelabor or intrapartum).
Similarly, evidence among women with T1DM [14,44], SLE [18,57], Crohn’s [52,58,59] or 
RA [18,31,34] suggests increased risk of preterm birth while reports of preterm birth risk 
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among women with MS are inconsistent. Two population-based studies report an increased 
preterm birth risk among women with MS [27,28], and four other studies report no increased 
risk [25,26,29,30]. No data are available regarding precursors of preterm birth or 
spontaneous versus induced deliveries among women with autoimmune disease.
Evidence for other prevalent complications associated with autoimmune disease is also 
inconclusive. For example, among women with RA, four studies report an increased risk of 
small for gestational age (SGA) [21,31,32,60], while four studies report no increased risk of 
SGA [16,22,33,34]. Evidence regarding neonatal intensive care unit (NICU) admission is 
also sparse with mixed results [15–17,22,33,35–40]. For certain autoimmune diseases like 
T1DM, and Crohn’s disease, studies are limited and none have been conducted among US 
populations [14,15,39,41].
Using a nationwide US cohort, we aimed to provide a more comprehensive description of 
the obstetric and neonatal risks among women with autoimmune disease and their infants. 
To better understand obstetric and neonatal risks associated with maternal autoimmune 
disease, we examined women in the Consortium on Safe Labor (CSL) diagnosed with 
T1DM, SLE, Crohn’s, MS, or RA. These diseases are heterogeneous and their target tissues 
vary (pancreatic β-cells for T1DM [61]; various tissues including musculoskeletal, renal, 
and central nervous system for SLE [62]; bowel in Crohn’s [63]; the nervous system in MS 
[64]; and musculoskeletal system in RA [65]).
2. Materials and methods
2.1. Consortium on Safe Labor
The CSL was a U.S. retrospective cohort study from 2002 to 2008 that abstracted labor and 
delivery information from electronic medical records from 19 U.S. hospitals. Data extracted 
for deliveries at 23 gestational weeks or later (n = 228,438) included: maternal socio-
demographic characteristics, medical, reproductive and prenatal history, labor and delivery 
summaries, postpartum and newborn data [66]. For these analyses, we excluded multifetal 
pregnancies (n = 5,063, 2.2%), mothers with thyroid disease (n = 3,772, 1.6%), mothers with 
other autoimmune disease (n = 1,764, 0.7%) such as unspecified diseases of connective 
tissue, thrombophilia, hemorrhagic conditions, ulcerative colitis, coeliac disease, Grave’s 
disease and Hashimoto’s thyroiditis, and participants from one site for which ICD-9 codes 
were not reported and no cases of the autoimmune diseases of interest were identified (n = 
12,318, 5.3%). Our final analytic sample included 205,521 deliveries. Institutional Review 
Boards approval was obtained at all participating sites and data are de-identified.
2.2. Autoimmune diseases of interest
Relatively common maternal autoimmune diseases were selected for analyses in part to 
ensure sufficient sample size. T1DM, SLE, Crohn’s, MS, and RA were identified using 
delivery admission electronic medical records and discharge ICD-9 codes (Supplementary 
Table 1). The sensitivity of these codes for obstetric conditions is generally good [66–68]. 
For women with multiple pregnancies during the study period, a diagnosis of autoimmune 
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disease was assumed for subsequent pregnancies (52 repeat pregnancies among women with 
autoimmune disease, 4.5% of pregnancies to women with autoimmune disease).
2.3. Obstetric and neonatal outcomes
Outcome variables were elected based on prevalence and prior studies: cesarean delivery 
(overall, pre-labor, after induced labor, and after spontaneous labor), preeclampsia, preterm 
birth (< 37 weeks of gestation; overall, spontaneous preterm delivery, indicated preterm 
delivery), small for gestational age, NICU admission, neonatal respiratory distress syndrome 
(RDS), and perinatal mortality (pregnancy loss ≥ 23 weeks of gestation through neonatal 
mortality ≤ 7 days) were identified from maternal and neonatal medical records 
supplemented with discharge ICD-9 codes (Supplementary Table 1).
2.4. Statistical analysis
Descriptive statistics were summarized by autoimmune disease status (Present/Absent). 
Binary Poisson regression models with the log link function and robust standard errors to 
account for repeat pregnancies estimated relative risks (RR) and 95% confidence intervals 
(95% CI) for the association between autoimmune disease and out-comes of interest. 
Women with autoimmune disease and their infants were compared to women without any 
autoimmune disease. Models were adjusted for maternal age (continuous), maternal race/
ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other), health insurance (public, 
private, other), marital status (married, divorced/widowed, single, unknown), smoking 
during pregnancy (yes/no), alcohol use during pregnancy (yes/no), any other chronic 
diseases (yes/no: type 2 diabetes, asthma, depression, heart disease, hypertension, renal 
disease) and census region (Northeast, West, South, Midwest), based on previous literature 
[4,20,22,27,31,41,48,52].
We also compared indications for cesarean delivery and precursors for preterm delivery by 
autoimmune disease status. All statistical analyses were conducted using SAS 9.4 (SAS 
Institute Inc., Cary, NC, USA). We did not adjust for multiple comparisons [69].
3. Results
3.1. Prevalence of autoimmune diseases
The prevalence of autoimmune diseases (cases per 1000 pregnancies) for the CSL 
population by demographic variables are presented in Table 1.
Black women had the highest rates of T1DM (2.9/1000) and SLE (1.3/1000), while white 
women had the highest rates of Crohn’s (1.4/ 1000), MS (1/1000), and RA (0.8/1000). 
Women with private insurance had the highest rates of SLE (1.1/1000), Crohn’s (1.1/1000), 
and MS (0.9/1000). Women with public insurance had the highest rate of T1DM (2.9/1000). 
Rates of T1DM, SLE, and Crohn’s varied by census region. Rates of T1DM were highest for 
women in the Midwest (3.1/1000) and the South (2.9/1000). Women in the South had the 
highest rate of SLE (1.4/1000), and women in the Northeast had the highest rate of Crohn’s 
disease (1.4/1000).
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Women with autoimmune disease and their infants generally experienced more adverse 
outcomes compared to women without autoimmune disease (Tables 2 and 3). Women with 
any of the examined autoimmune diseases, when compared to women without autoimmune 
disease, had significantly higher rates of cesarean delivery, pre-labor cesarean delivery, 
preterm birth, and spontaneous preterm birth. Women with T1DM, SLE, or Crohn’s also had 
higher rates of preeclampsia and indicated preterm birth. Women with T1DM or SLE had 
similarly high rates of poor obstetric outcomes, except for cesarean delivery, where T1DM 
was associated with the highest rates (Table 2).
Only women with SLE or RA had significantly higher rates of SGA, while women with 
T1DM had lower rates of SGA as expected, compared to women without autoimmune 
disease.
3.2. Risk of adverse obstetric and neonatal outcomes
Results were similar in adjusted analyses (Table 3), with all autoimmune diseases associated 
with increased risk for cesarean delivery, including for pre-labor cesarean and cesarean after 
induced or spontaneous labor, and preterm birth, including both indicated and spontaneous 
preterm birth.
Models adjusted for maternal age, maternal race/ethnicity, preconception body mass index, 
health insurance, marital status, smoking in pregnancy, alcohol use in pregnancy, other 
chronic diseases, and census region.; *p < 0.05 indicates rates among women with 
autoimmune disease different than rates among women without autoimmune disease.
Women with T1DM were at increased risk for most poor obstetric outcomes, except for 
SGA (RR:0.61, 95% CI: 0.43, 0.86). Similarly, women with SLE were at increased risk for 
most obstetric outcomes.
Infants born to women with autoimmune disease, compared to those born to women without 
autoimmune disease, appear to have elevated risk for most adverse neonatal outcomes, but 
many associations did not reach statistical significance (Tables 2 and 3). However, compared 
to infants born to women without autoimmune disease, infants born to women with T1DM 
were three times more likely to experience RDS (RR: 3.62; 95% CI: 2.84, 4.62), and twice 
as likely to experience perinatal mortality (RR: 2.35; 95% CI: 1.12, 4.91), and had a 25% 
risk of NICU admission (RR: 1.25; 95% CI: 1.16, 1.35). Infants born to women with SLE 
had similar increases in risk for RDS and NICU admission.
3.3. Intrapartum cesarean delivery and indicated preterm delivery
As risk of cesarean or preterm delivery were increased for women with autoimmune 
diseases, we examined indications for intrapartum cesarean deliveries (Table 4) and for 
indicated preterm deliveries (Table 5).
For intrapartum cesarean deliveries (Table 4), failure to progress was the most common 
indication for women with T1DM, Crohn’s, MS or RA. Among women with T1DM, 
Crohn’s or MS, rate of failure to progress was significantly higher than among women 
without autoimmune disease. Among women with SLE, non-reassuring fetal heart rate 
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tracing was the most common indication and was nearly three-fold higher than among 
women without autoimmune disease. Compared to women without autoimmune disease, 
women with T1DM, SLE, Crohn’s or RA had three-to five-fold higher rates of hypertensive 
disorders as indication for intrapartum cesarean delivery. Women with T1DM had the 
greatest number of significantly higher rates of indications, including prior uterine scar 
(90.7/1000), fetal distress (78.9/1000) and elective (47.3/1000).
For indicated preterm deliveries (Table 5), rates of preeclampsia, superimposed 
preeclampsia, and maternal conditions were higher among women with T1DM, SLE, 
Crohn’s or MS compared to women without autoimmune disease. Women with T1DM had 
significantly higher rates for nine indications, including chronic hypertension (15.77/1000), 
fetal anomaly (27.6/1000), fetal macrosomia (1.97/1000), and history of previous pregnancy 
condition (27.61/1000). Women with SLE had statistically significant higher rates for six 
indications, including chorioamnionitis (4.95/1000), fetal anomaly (24.75/1000), and other 
fetal conditions (14.8/1000).
4. Discussion
Despite advances in management of autoimmune disease that aid women in fulfilling family 
plans, pregnant women with autoimmune diseases continue to experience increased risk of 
poor obstetric and neonatal outcomes. We found the risk for cesarean delivery after 
spontaneous or induced labor was similar among women with T1DM. However, the 
increased risk of overall cesarean delivery for women with SLE, Crohn’s, MS or RA may 
have been due to increased risk of cesarean delivery after spontaneous labor. The increased 
risk of preterm delivery may be driven by indicated preterm deliveries among women with 
T1DM or SLE, but both indicated and spontaneous preterm delivery risk were elevated for 
women with Crohn’s, MS or RA.
The richness of the CSL data allowed us to examine indications for cesarean delivery and 
preterm delivery. Despite heterogeneity of symptoms across types of autoimmune disease, 
failure to progress, nonreassuring fetal heart rate tracing, and maternal hypertensive 
disorders were common indications for intrapartum cesarean section across types of 
autoimmune disease, with evidence particularly strong among women with T1DM (Table 4). 
Preeclampsia and maternal comorbidities were more likely to be indicators for preterm 
delivery among women with autoimmune diseases compared to women without autoimmune 
disease (Table 5). Examining these indications can provide clinicians with new information 
on risk factors for poor obstetric outcomes among women with autoimmune disease.
These observations among women with a heterogenous set of autoimmune diseases 
underscores the importance of immunologic health during pregnancy, and the importance of 
a mother’s immunologic health for her neonate. For instance, women with T1DM or SLE 
had similarly increased risk for a range of adverse obstetric and neonatal outcomes, despite 
heterogenous symptoms and different target tissues. The observations among women with 
T1DM or SLE align with previous evidence regarding cesarean delivery, preterm delivery, 
and small for gestational age births [12,14,17,18,32,41,44–48,57]. We provide the first 
Williams et al. Page 6













evidence among a U.S. cohort that infants born to women with T1DM or SLE were at 
increased risk for RDS and NICU admission.
Obstetric risks for women with MS or RA have been underexamined in extant literature. Our 
observation of increased preterm delivery risk among women with MS suggests this 
association merits further attention. We also add evidence suggesting an increased risk of 
SGA births among women with RA.
The results which were not statistically significant still provide interesting details regarding 
obstetric and neonatal risks among women with autoimmune disease. For example, the risk 
estimates for cesarean delivery after spontaneous labor suggest increased risk among women 
with SLE, Crohn’s, MS or RA, but with a lack of statistical power. Similarly, results suggest 
infants of women with Crohn’s may be at increased risk for SGA and RDS, and women with 
RA may be at increased risk for cesarean delivery overall and after spontaneous labor, at 
increased risk for overall and indicated preterm delivery, and RDS, although estimates were 
imprecise. Additionally, the differences in magnitude of effects observed across autoimmune 
diseases and obstetric outcomes are notable. For example, the risk for cesarean delivery after 
induced labor among women with SLE, Crohn’s, MS or RA is close to null. These results 
differ from the 250% increased risk for cesarean delivery after induced labor among women 
with T1DM, suggesting the risk of poor outcomes is not uniform across autoimmune 
diseases.
This study has several notable strengths. This is the first study of a large, U.S.-based cohort 
of pregnant women with a heterogeneous group of autoimmune diseases that assessed 
multiple obstetric and neonatal outcomes. While the CSL is not a nationally representative 
sample, the CSL is geographically varied, racially/ethnically diverse and includes women 
across the reproductive age range, it is a good representation of the pregnancy outcomes 
among women with autoimmune diseases in the U.S. To the best of our knowledge, this is 
the first study to examine a large, U.S.-based cohort in which women with T1DM are 
compared to general population controls. Additionally, we provide the first evidence of 
NICU admission risk among the infants of women with a variety of autoimmune diseases. 
We also provide novel evidence that infants born to women with SLE and T1DM are at 
increased risk for RDS. The neonatal risks observed are not only important in the short-term, 
but also can impact the health of these children as they age [70,71]. Cohort studies enriched 
with children born to mothers with autoimmune disease may be required to fully explore 
these risks due to the rarity of autoimmunity in pregnancy.
Our novel observations fill existing knowledge gaps that can inform clinicians counseling 
women with autoimmune disease regarding their family plans. There are few resources for 
clinicians that evaluate common autoimmune disorders and identify the obstetric and 
neonatal risks for women who are affected. This information allows women with 
autoimmune disease to make better informed decisions regarding their reproductive health in 
consultation with their physicians.
The retrospective cross-sectional design of the CSL limited our ability to consider two 
important aspects of autoimmune disease. First, we do not have data on diagnosis date to 
Williams et al. Page 7













determine the length of time with disease prior to pregnancy. Evidence suggests women who 
have had an autoimmune disease for a longer period of time have worse health outcomes 
compared to women who have had the same autoimmune disease for a shorter period of time 
[72]. Secondly, we do not have data regarding disease management and symptomology 
during pregnancy. As autoimmune diseases are often managed on a daily basis, the disease 
activity during pregnancy is known to be an important determinant of pregnancy outcomes. 
Additionally, CSL data lacks medication use and biologic measures that would be helpful to 
assess mechanisms linking autoimmune disease and pregnancy outcomes.
Potential mechanisms linking maternal autoimmune disease with obstetric and neonatal 
outcomes are not well understood. Longitudinal investigations of immunologic health of 
pregnant women with autoimmune diseases are needed to better understand the general 
physiology of autoimmune disease during pregnancy, and to understand how daily 
management of these diseases, including disease flare ups, impacts pregnancy. While 
advances in the treatment and management of autoimmune disease have aided women in 
fulfilling their family plans, our data indicate that women with autoimmune disease may still 
have high risk for adverse outcomes.
Relying on the ICD-9 codes for autoimmune diagnoses may have missed several cases, but 
we expect that these conditions would be recorded in the medical records since they are 
likely to cause complications of pregnancy and are relevant for labor and delivery. Since the 
delivery admission hospitalization record has limited data on maternal chronic disease, we 
assume the reported risks of poor obstetric and neonatal outcomes among women with 
autoimmune disease are average risks. We recognize that unmeasured factors such as disease 
severity, length of time with disease, and management of disease may result in a risk profile 
differing from our observations. Clinical researchers can build upon this foundation to better 
understand how risk profiles may differ in order to provide better treatment options and 
allow for more informed decision making among their patients.
While we did not have treatment or disease severity data, recent recommendations suggest 
women with autoimmune disease wishing to become pregnant should discuss treatment 
options with their clinicians [73–79]. Preconception management may include altering 
medication, as certain treatments for RA, Crohn’s and SLE are contraindicated with 
pregnancy [74,75,77,78]. Management of preconception blood glucose levels may limit risk 
of nephropathy among women with T1DM, and nephropathy has been suggested as a 
potential mechanism for increased risk of preeclampsia among women with T1DM [73], and 
poor glucose control during pregnancy and labor may increase risk for perinatal mortality 
[80]. During pregnancy, standard course of care is typically recognized as safe for mother 
and fetus, unless medications have been contraindicated for pregnancy [73–79]. Infants born 
to women with autoimmune disease may require initial NICU admission or additional 
examinations per hospital policy, thus clinicians and pregnant women with autoimmune 
disease should discuss potential care plans covering the immediate postpartum period. For 
example, women with T1DM should be aware that NICU admission, blood glucose testing, 
blood lipids testing, and echocardiograms may be included as standard course of care for 
their infants [79]. Furthermore, clinicians should closely monitor blood glucose levels of 
women with T1DM during labor and delivery, and insulin drip during labor has been 
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recommended to maintain blood glucose levels [80]. These findings of increased risk of 
NICU admission and RDS among neonates suggest more attention to neonates of mothers 
with autoimmune disease is warranted.
In conclusion, in this comprehensive examination of multiple autoimmune diseases and 
various obstetric and neonatal outcomes in a national sample of U.S. women and their 
infants, maternal autoimmune disease was associated with poor obstetric and infant 
outcomes, especially preterm birth. These increased risks were observed despite the 
heterogeneity of symptomology across various autoimmune diseases, highlighting the 
importance of research to better understand immunologic function during pregnancy and to 
better guide prenatal care and inform patient-provider decision making regarding pregnancy 
for women with autoimmune disease.
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